anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Clonidine hydrochloride USP is a centrally acting alpha-agonist hypotensive agent available as tablets for oral administration in three dosage strengths: 0.1 mg, 0.2 mg and 0.3 mg. The 0.1 mg tablet is equivalent to 0.087 mg of the free base.

  


The inactive ingredients are corn starch, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polysorbate 80, in addition 0.1 mg and 0.2 mg contains D&C Yellow No. 10, 0.1 mg and 0.3 mg contains FD&C Blue No. 1, and 0.3 mg contains FD&C Blue No. 2.   
Clonidine hydrochloride is an imidazoline derivative and exists as a mesomeric compound. The chemical name is 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride. The following is the structural formula:

Clonidine hydrochloride is an odorless, bitter, white or almost white crystalline powder. Soluble in water and ethanol, slightly soluble in chloroform.
behavioral protocol. Letters (vowel and consonant; upper- or lower- case) are presented in several colours into successive blocks. Each block included a series of eight letters. Each colour required a specific task given by a fixed rule (contextual control) but for some colour, the rule changes sometimes (episodic control). Participants are informed that payoffs vary according to their own performance. A frame indicates essay with bonus reward. Moreover a dashed frame indicates a low-bonus reward and a solid frame means a high-bonus reward. Thus different blocks are designed: low-incentive block and high incentive block.

This reward increased from standard to bonus motivation in high-incentive block (contextual motivation) and from low to high according to the type of blocks (episodic motivation) Reaction time may be higher in bonus reward Patients with schizophrenia are not sensitive to contextual motivation, and therefore patients should behave differently than control in contextual motivation.
In clinical trials, most of the reported side effects were mild to moderate in severity and were reversible upon discontinuation of the drug. Potentially serious side effects of angioedema and cholestatic jaundice were reported rarely. Approximately 0.7% of the patients (adults and pediatric patients) from the 5-day multiple-dose clinical trials discontinued azithromycin therapy because of treatment-related side effects. In adults given 500 mg/day for 3 days, the discontinuation rate due to treatment-related side effects was 0.6%. In clinical trials in pediatric patients given 30 mg/kg, either as a single dose or over 3 days, discontinuation from the trials due to treatment-related side effects was approximately 1%. (See DOSAGE AND ADMINISTRATION.) Most of the side effects leading to discontinuation were related to the gastrointestinal tract, e.g., nausea, vomiting, diarrhea, or abdominal pain. (See CLINICAL STUDIES IN PEDIATRIC PATIENTS.)
Experimental: Solid tumors Part 1 - Dose-escalation of SYHA1801 in patients with advanced solid tumors.Daily dosing of SYHA1801 on Days 1 and 4-31 of 28-day cycle. Escalating dose cohorts.
Online hemodiafiltration (OL-HDF) has been recently associated with better patient survival in comparison with standard hemodialysis in some large observational studies (Canaud et al, KI, 2006; Vilar et al, CJASN , 2009) supporting the hypothesis that convection can improve patients outcomes. Moreover, it has been demonstrated in randomized controlled trials (Locatelli et al, Journal American Society of Nephrology, 2010) that OL-HDF significantly reduced the frequency of intradialytic hypotension. Nonetheless, the associated comorbidities and ageing of dialysis population require further devices able to improve treatment tolerance. Among these tools, the sodium profiling and biofeedback system seem to be promising to accomplish this task. But the correct intradialytic sodium balance is still far away today to be easily achieved. The use of an automated adaptive system dialysis to the sodium profiling has been investigated in a feasibility trial (Colì et al International Journal Artificial Organs, 2003). They also investigated the impact of such a device on treatment tolerance.

The aim of this randomized multinational multicenter controlled trial is to evaluate the impact of sodium profiling applied to a endogenous hemodiafiltration technique on the intradialytic cardiovascular stability in comparison to standard no profiled endogenous hemodiafiltration.
The present invention relates to the field of biotechnology, and provides a kit and method for inducing stem cells to differentiate into natural killer (NK) cells, and a use of the kit. In the kit, a culture medium having clear chemical components, chemical small molecules, and cytokines are used. The kit does not involve substances such as serum which are easy to cause unstable factors such as batch differences, is cheaper in price than a known commercial differentiation culture medium, and reduces the differentiation period. The present invention further provides a pharmaceutical composition and method for treating glioblastoma (GBM), particularly drug-resistant GBM, and a use of the pharmaceutical composition. Specifically, the present invention relates to treatment for GBM by combining immune cells and a chemotherapy drug. More specifically, the present invention relates to synergistic treatment for TMZ drug-resistant GBM by combining NK cells and TMZ.
Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa dose. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
The utility model relates to a thermostable tablet composition containing vitamin K, which finds application in the manufacturing of tablets for human use. The components of the composition are in a quantitative ratio with each other in % by weight relative to the total weight as follows: vitamin K oil concentrate from 18 to 20%; corn starch filler from 38 to 40%; microcrystalline cellulose binder from 15 to 17%; hydroxypropyl methylcellulose plasticizer from 2 to 4%, distilled monoglycerides from 10 to 12%, palm oil from 10 to 12%, calcium carbonate from 0.00 to 13%. The granular and coated composition of vitamin K consists of a granular core containing a filler and at least one vitamin applicable in the manufacture of tablets in the appropriate dosage. Each granule is coated with two coating layers, as each layer has a different melting point, the second layer has a higher melting point, as the temperature difference is from 5 to 10 degrees Celsius. As a coating agent for the first layer is preferable to use monoglycerides from vegetable oils or a mixture of vegetable oil with the addition of monoglycerides. What can be used as a vegetable oil is soybean, rapeseed, corn, sunflower, olive, palm and other natural oils of vegetable origin. The concentration of added monoglyceride is determined by the requirement that the melting point of the resulting mixture to be between 50 and 65 degrees Celsius. As a coating agent for the second layer is used an agent with a melting point between 65 and 75 degrees Celsius. Such an agent can be achieved by mixing vegetable oil with monoglycerides, or to be used hydrogenated oil, for example hydrogenated palm oil alone or with added monoglycerides for further modification of the melting point. The presence of two separate coating layers of hydrophobic material effectively protects the core of the granule and the enzyme from the penetration of moisture from the environment and provides increased protection of the granule during tableting.
Hypertension is the most prevalent modifiable risk factor for stroke and is associated with worse functional outcomes. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid (SAHA) modulates gene expression and has emerged as a promising therapeutic approach to reduce ischaemic brain injury. Here, we have tested the therapeutic potential of SAHA administered during reperfusion in adult male spontaneously hypertensive (SHR) rats subjected to transient middle cerebral artery occlusion (tMCAO; 90 min occlusion/24 h reperfusion). Animals received a single dose of SAHA (50 mg/kg) or vehicle i.p. at 1, 4, or 6 h after reperfusion onset. The time-course of brain histone H3 acetylation was studied. After tMCAO, drug brain penetrance and beneficial effects on behavioural outcomes, infarct volume, oedema, angiogenesis, blood-brain barrier integrity, cerebral artery oxidative stress and remodelling, and brain and vascular inflammation were evaluated. SAHA increased brain histone H3 acetylation from 1 to 6 h after injection, reaching the ischaemic brain administered during reperfusion. Treatment given at 4 h after reperfusion onset improved neurological score, reduced infarct volume and oedema, attenuated microglial activation, prevented exacerbated MCA angiogenic sprouting and blood-brain barrier breakdown, normalised MCA oxidative stress and remodelling, and modulated brain and cerebrovascular cytokine expression. Overall, we demonstrate that SAHA administered during early reperfusion exerts robust brain and vascular protection after tMCAO in hypertensive rats. These findings are aligned with previous research in ischaemic normotensive mice and help pave the way to optimise the design of clinical trials assessing the effectiveness and safety of SAHA in ischaemic stroke.
Postoperative hoarseness, sore throat, and vocal cord injuries are common complications after general anesthesia. The incidence of postoperative hoarseness is as frequent as 50% after short-term tracheal intubation. In the past, several risk factors for postoperative hoarseness and laryngeal injury have been identified, including demographic factors, quality of tracheal intubation and technical factors such as endotracheal tube size. One-lung ventilation during thoracotomy can be achieved via two basic techniques: (1) use of a double-lumen endotracheal tube (DLT) consisting of an endotracheal and an endobronchial lumen allowing independent single-lung ventilation ; or (2) use of an endobronchial blocker such as the Arndt blocker, which allows lung collapse distal to the occlusion. It has been recently demonstrated that DLT and endobronchial blocker are similar in their efficacy to achieve lung isolation for elective thoracic surgery. No data are available yet about the influence of the chosen technique on postoperative hoarseness, vocal cord injuries, sore throat, and bronchial injuries. Published data of Stout et al. imply that the incidence of postoperative hoarseness and vocal cord injury might be directly correlated with size of the used endotracheal tube. During thoracoscope assisted mitral valve replacement cardiac surgery, excellent lung isolated was not required. One-lung ventilation with the other lung collapsed is used to achieve a better exposure and assist the surgery. During the cardiac surgery under cardiopulmonary bypass, heparinization will lead to uncontrolled hemorrhage if there is endotracheal tube insertion associated injury. In addition, DLTs need to be exchanged for a single-lumen tube before the patient transferring to cardiac care unit for postoperative ventilatory support. This may result in second time injury. Investigators hypothesized that using a bronchial blocker to achieve one-lung ventilation may result in a lower incidence of clinically relevant laryngeal and bronchial morbidity after thoracoscope assisted mitral valve replacement cardiac surgery compared with a control group intubated with a DLT.
The purpose of the first phase of this study (phase I) is to find the dose of a new therapy, the MG1 Maraba/MAGE-A3 (MG1MA3) virus that can be given alone and in combination with the Adenovirus/MAGE-A3 (AdMA3) virus. In the first part of the study, patients may receive the Maraba virus, the Adenovirus or both viruses. To identify the highest safe dose of the Maraba virus alone or in combination the study will start at a dose lower than the one that does not cause side effects in animals. Participants are given one or both of these therapies and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If serious side effects are seen in patients at the first dose level, doses of MG1MA3 may be lowered in subsequent patients. If the side effects are not serious, then more potential participants are asked to join this study and are given higher doses. This will continue until the maximum feasible dose level is reached or one of the lower doses is found that causes serious but temporary side effects. Doses higher than that will not be given.
A hands-free speech-based natural language processing clinical decision support (CDS) system configured to operate in conjunction with a stationary or mobile base device speech system to receive voice commands from a user. A dialog may be conducted with the user in multiple turns, where each turn comprises user speech and a speech response by the speech system. The user speech in any given dialog turn may be provided from the base device. This speech system dialog is directed by a computer program finite state engine. Rule data for the state engine is retrieved from an internet cloud database by a computer program function and is applied to the speech dialog system in order to prompt the user for specific information. This user supplied information is used as inputs to the computer program that in turn refine the speech dialog and requests for additional information. Once all information required to make the CDS recommendation have been received, the computer program applies an algorithm to generate a set of recommendations from which the user can select the best option for their patient.
Herbaspirillum huttiense is an opportunistic pathogen associated with rare cases of bacteremia. In this case report, H huttiense was isolated from blood samples collected from an intravenous catheter (incubated for 20.8 hours) and a peripheral vein (incubated for 14.16 hours) of a lung adenocarcinoma patient. Positive blood culture bottles were subjected to smear preparation, and Gram staining and microscopic examination revealed the presence of gram-negative rods in both aerobic bottles. We used the VITEK MS automatic microbial mass spectrometry system, VITEK 2 Compact automatic microbial analysis system, and high-throughput nucleic acid sequencing for accurate identification of the isolate. It is noteworthy that although the VITEK 2 Compact identified the isolate as Burkholderia cepacia, confirmation through VITEK MS mass spectrometry and 16S ribosomal DNA (rDNA) sequencing identified it as H huttiense. Subsequently, antimicrobial susceptibility testing was performed using the broth microdilution method, following the guidelines for nonfermenting gram-negative bacilli provided by the Clinical and Laboratory Standards Institute. This case highlights the possibility of misidentification of H huttiense as B cepacia by VITEK 2 Compact in certain situations, emphasizing the importance of considering uncommon pathogens, such as H huttiense, in the context of bacteremia in cancer patients.
After discharge from the acute rehabilitation facility, participants in the stroke RE group will participate 3 days a week for 10 weeks in robotic exoskeleton gait training provided by a trained, licensed physical therapist. Participants will be permitted to participate in additional prescribed standard physical therapy on their own.
Program included traditional exercises intended for strengthening back, abdominal, pelvis and shoulder girdle muscles and muscles in convex side of the curve, stretching exercises especially for the concave side of the curve, flexibility exercises for spine, postural training and breathing exercises. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
The invention discloses a fatty acid-trimethyl chitosan polymer modified by a lactobionic acid, a preparation method and an application. The fatty acid-trimethyl chitosan polymer modified by the lactobionic acid is an active targeting nano micelle carrier material. A trimethyl chitosan with a good water-solubility is used as a carrier material, the hydrophobic modification is performed by a fatty acid, and then the surface modification is performed by the lactobionic acid to obtain a polymer micelle with the lactobionic acid which mediates tumor tissue target. Harmine is used as a model drug to prepare a drug-loaded nano-micelle in a rubbing and self-assembly mode. A test confirms that the drug loading capacity and encapsulated ratio of the drug-loaded nano-micelle are high, the slow-release property is achieved, cells are effectively taken in through a lactobionic acid receptor pathway, and distribution of drugs on the tumor tissue is increased, so that the curative effect is improved, the toxic and side effect is reduced, and targeted therapy is achieved. The fatty acid-trimethyl chitosan polymer modified by the lactobionic acid, the preparation method and the application provide an ideal novel drug carrier and a preparation form for antitumor drugs with slightly solubility.
Transdermal delivery compositions and topical compositions for application to the skin are provided. The transdermal delivery composition includes at least two penetrants working synergistically but by disparate biochemical pathways. In one embodiment, the transdermal delivery system includes benzyl alcohol and lecithin organogel. The transdermal delivery compositions are used in a variety of topical compositions as a means of transdermally delivering and topically administering different drugs and agents, including compositions promoting collagen biosynthesis, retinoids and skin lighteners, chemical denervation agents such as BOTOX®, anti-fungal agents, anesthetics and non-steroidal anti-inflammatory drugs (NSAIDs). In addition, these topical compositions may be used in combination with non-ablative treatment modalities, such as microdermabrasion, laser-based skin remodeling and radio- frequency-based skin remodeling. LES/les
A method for the treatment, control and/or prophylaxis of a viral infection in a mammal is disclosed. The method involves the administration to the mammal of an effective amount of a galactofucan sulfate from Undaria. The method particularly discloses the method of treatment, control and/or prophlyaxis of a herpes family type virus in a human. The Applicant has shown that galactofucan sulfate extracts from Undaria are successful at treating or ameliorating symptoms associated with an active herpes family type viral infection and also at reducing reoccurrences of symptoms associated with a latent herpes family type viral infection. Also disclosed is a process for obtaining the galactofucan sulfate from Undaria. The process involves extracting plant material from Undaria in an acidic aqueous solution, at a temperature between 0-30°C, neutralising the extracted solution and separating out material with a molecular weight less than 10,000 Daltons.
Participants were given dietary blueberries (2 cups) and soluble fiber (12g). They also received nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% heart rate reserve (HRR) three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will follow pre-emptive management per institutional standard.
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
FIELD: medicine. ^ SUBSTANCE: invention relates to biotechnology and represents pharmaceutical compositions and method for treatment of diseases associated with amyloid depositions A in patient's brain, such as Alzheimer's disease. Method includes introduction of immunogenic fragment A with absence of T-cell epitope, able to induce effective immune response in form of antibodies to A. Pharmaceutical compositions include immunogenic fragment, chemically bound with carrier molecule, which can be introduced with adjuvant. ^ EFFECT: invention is efficient as vaccine against Alzheimer's disease. ^ 18 cl, 13 dwg, 9 tbl, 10 ex
The total ATG dose was 10mg/kg. ATG was intravenously infused every day from day -5 to day -2.
Given the increase in students with learning disabilities entering university, we investigated a broader group-students with a history of reading difficulties (HRD)-who are known to be at risk of academic struggles. We identified the self-reported reading challenges and strategies of university students with HRD (n = 49) and those with no history of reading difficulties (NRD; n = 88) and examined group differences and relations with first-year grade point average (GPA). Students with HRD reported more difficulties with perceived reading comprehension, concentration, and reading speed than students with NRD. Groups differed in use of reading strategies: Students with HRD were descriptively more likely to reduce reading volume by using alternative materials and chose to read based on text length and availability of alternative materials. For both groups, reading completion and concentration strategies were positively related to GPA, while perceived difficulty with reading comprehension and choosing to read based on interest were negatively related to GPA. Some strategies were negatively associated with GPA for students with NRD, but not for students with HRD. Findings revealed the challenges that students with HRD experience with reading in university and identified strategies, potentially adaptive or maladaptive, that they used to manage their academic reading load.